サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1675444

免疫療法薬市場：薬剤タイプ別、治療領域別、エンドユーザー別、地域別、2025-2033年

Immunotherapy Drugs Market Report by Drug Type, Therapy Area, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 149 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
免疫療法薬市場：薬剤タイプ別、治療領域別、エンドユーザー別、地域別、2025-2033年
出版日: 2025年03月01日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

免疫療法薬市場の世界市場規模は2024年に2,295億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに4,494億米ドルに達し、2025～2033年の成長率（CAGR）は7.36%になると予測しています。高齢化に伴うさまざまながん種の有病率の増加、個別化治療薬に対する需要の高まり、早期発見・早期治療に対する個人の意識の高まりなどが、市場を牽引する主な要因となっています。

免疫療法薬は、病気と闘ったりコントロールしたりするために免疫系を利用したり変更したりするように設計された治療法です。特定の細胞やタンパク質に作用し、健康な組織への害を最小限に抑えます。免疫療法薬は、他の治療法と比較して、耐性ができる可能性を減らし、より良い結果をもたらし、副作用も少ないです。メラノーマ、肺がん、乳がんなど、さまざまな種類のがんの治療に利用されています。また、特定のアレルギー反応の管理や、関節リウマチ、ループス、多発性硬化症などの病気の治療にも使用されています。このほか、慢性炎症性疾患のコントロールにも有効であることから、免疫療法薬の需要は世界中で増加しています。

製薬業界の台頭と世界の薬局の拡大が、良好な市場見通しをもたらしています。さらに、バイオテクノロジー企業、製薬企業、研究機関の戦略的提携や合併・買収（M&A）が、免疫療法製品の研究開発・商業化活動を支えています。さらに、研究開発（R&D）活動における人工知能（AI）とビッグデータ解析の統合は、効率と精度を高めています。この技術統合により、標的の迅速な特定、臨床試験の最適化、患者の反応予測が可能となっています。

免疫療法薬の市場傾向/促進要因：

標的疾患の有病率の増加

ライフスタイルの変化や不健康な食事パターンにより、様々な種類のがんの発生が増加しており、免疫療法のような革新的で効果的な治療に対する需要が高まっています。さらに、早期発見と個別化治療の必要性が、患者やヘルスケアプロバイダーにこうした先進的な治療法の採用を促しています。これとは別に、急速な都市化や有害な自動車排気ガスによる汚染レベルの上昇が様々な慢性疾患の原因となっており、免疫療法治療の新たな機会を生み出しています。さらに、腫瘍やがん、その他の健康状態に罹患しやすい高齢化人口の増加が、免疫療法薬のような効果的な治療法や技術の必要性を高めています。

個別化医療の採用

より患者中心のアプローチを推進するため、様々な医療分野で個別化医薬品の利用が増加していることが、市場にプラスの影響を与えています。さらに、次世代シークエンシングやバイオマーカー分析などの高度な診断ツールの開発により、特定の免疫療法の対象となる患者を正確に特定できるようになっています。このような診断の進歩は、早期介入を容易にし、個別化された治療計画を可能にし、免疫療法の全体的な効果を高めるのに役立っています。これとは別に、個別化免疫療法は試行錯誤の可能性を減らします。さらに、このような的を絞ったアプローチにより、効果のない治療の使用を最小限に抑え、不必要な副作用を回避し、早期回復を促し、ヘルスケアコストを削減することができるため、市場の成長に寄与しています。

政府と規制当局の支援

各国の政府・規制機関は、免疫療法薬や治療法の開発に継続的に注力しており、市場の見通しを良好なものにしています。さらに、新規免疫療法の開発や既存免疫療法の最適化に必要な綿密な研究を行うための財政支援も行われています。これとは別に、政府、研究機関、非公開会社のパートナーシップが市場の成長を支えています。このような協力関係は、知識の交換を促進し、国境を越えた画期的な免疫療法治療の開発を加速させています。さらに、政府によるヘルスケア政策の導入も、免疫療法の導入と償還を後押ししています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の免疫療法薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • モノクローナル抗体
  • ワクチン
  • インターフェロンαとβ
  • インターロイキン

第7章 市場内訳：治療領域別

  • がん
  • 自己免疫疾患・炎症性疾患
  • 感染症
  • その他

第8章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
図表

List of Figures

  • Figure 1: Global: Immunotherapy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Immunotherapy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Immunotherapy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Immunotherapy Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Immunotherapy Drugs Market: Breakup by Therapy Area (in %), 2024
  • Figure 6: Global: Immunotherapy Drugs Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Immunotherapy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Immunotherapy Drugs (Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Immunotherapy Drugs (Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Immunotherapy Drugs (Interleukins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Immunotherapy Drugs (Interleukins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Immunotherapy Drugs (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Immunotherapy Drugs (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Immunotherapy Drugs (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Immunotherapy Drugs (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Immunotherapy Drugs (Other Therapy Areas) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Immunotherapy Drugs (Other Therapy Areas) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Immunotherapy Drugs (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Immunotherapy Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Immunotherapy Drugs (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Immunotherapy Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Immunotherapy Drugs (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Immunotherapy Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Immunotherapy Drugs Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Immunotherapy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Immunotherapy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Immunotherapy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunotherapy Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Immunotherapy Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Immunotherapy Drugs Market Forecast: Breakup by Therapy Area (in Million USD), 2025-2033
  • Table 4: Global: Immunotherapy Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Immunotherapy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Immunotherapy Drugs Market: Competitive Structure
  • Table 7: Global: Immunotherapy Drugs Market: Key Players
目次
Product Code: SR112025A6639

The global immunotherapy drugs market size reached USD 229.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 449.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.36% during 2025-2033. The growing prevalence of different cancer types due to the aging population, rising demand for personalized medicines, and the increasing awareness among individuals about early detection and treatment are some of the major factors propelling the market.

Immunotherapy drugs are medical treatments designed to utilize or modify the immune system to fight or control diseases. They focus on specific cells and proteins and aid in minimizing harm to healthy tissues. They reduce the likelihood of developing resistance, offer better outcomes, and have fewer side effects as compared to other treatments. They are utilized in treating various types of cancers, including melanoma, lung, and breast cancer. They are also used in managing specific allergic reactions and treating diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Besides this, as they are effective in controlling chronic inflammatory diseases, the demand for immunotherapy drugs is increasing across the globe.

The rise in the pharmaceutical industry and the expansion of pharmacies worldwide is offering a favorable market outlook. Moreover, strategic collaborations and mergers and acquisitions (M&A) between biotech firms, pharmaceutical companies, and research institutions are supporting the research, development, and commercialization activities of immunotherapy products. Furthermore, the integration of artificial intelligence (AI) and big data analytics in research and development (R&D) activities is enhancing efficiency and precision. This technological integration is enabling the rapid identification of targets, optimization of clinical trials, and prediction of patient responses.

Immunotherapy Drugs Market Trends/Drivers:

The increasing prevalence of target diseases

The rising occurrence of different types of cancer due to lifestyle changes and unhealthy dietary patterns is catalyzing the demand for innovative and effective treatments like immunotherapy is growing. Additionally, the early detection and need for personalized therapy options are encouraging patients and healthcare providers to adopt these advanced treatment alternatives. Apart from this, rapid urbanization and rising pollution levels due to harmful vehicular emissions are resulting in various chronic diseases, which is creating new opportunities for immunotherapy treatments. Furthermore, the increasing aging population, which is highly susceptible to tumor, cancer, and other health conditions, is driving the need for effective treatments and technologies, like immunotherapy drugs.

Adoption of personalized medicines

The increasing utilization of personalized medicines in various medical fields to promote a more patient-centered approach is positively influencing the market. Additionally, the development of advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, is enabling the precise identification of patients for specific immunotherapies. These advancements in diagnostics facilitate early intervention and allow for personalized treatment plans, which aid in enhancing the overall effectiveness of immunotherapy. Apart from this, personalized immunotherapies reduce the likelihood of trial-and-error approaches. Furthermore, this targeted approach minimizes the use of ineffective treatments, avoids unnecessary side effects, facilitates quicker recoveries, and reduces healthcare costs, which is contributing to market growth.

Governmental and regulatory support

Governments and regulatory bodies of various countries are continuously focusing on the development of immunotherapy drugs and therapies, which is offering a favorable market outlook. Additionally, they are providing financial support for conducting the in-depth studies required to develop novel immunotherapies and optimize existing ones. Apart from this, partnerships between governments, research institutions, and private companies are supporting market growth. These collaborations facilitate knowledge exchange and accelerate the development of groundbreaking immunotherapy treatments across borders. Furthermore, the introduction of several supportive governmental healthcare policies is encouraging the adoption and reimbursement of immunotherapies.

Immunotherapy Drugs Industry Segmentation:

Breakup by Drug Type:

  • Monoclonal Antibodies
  • Vaccines
  • Interferons Alpha and Beta
  • Interleukins

Monoclonal antibodies represent the largest market segment

Breakup by Therapy Area:

  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases
  • Others

Cancer accounts for the majority of the market share

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals hold the majority of the market share

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest immunotherapy drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share as the region has a well-established healthcare infrastructure that allows for the efficient distribution and utilization of immunotherapy drugs. Sophisticated medical facilities and well-trained healthcare professionals facilitate the widespread adoption of these treatments. Additionally, the region witnesses substantial investments from public and private sectors in healthcare and biotechnology, which facilitates research, drug development, and commercialization of immunotherapy products. Apart from this, the regulatory bodies in North America, such as the Food and Drug Administration (FDA), offer a conducive environment for drug approval. Furthermore, strategic collaborations between academia, biotech firms, and pharmaceutical companies ensure a dynamic environment for continuous innovation and growth in the field of immunotherapy.

Competitive Landscape:

Companies are actively engaged in various activities to stay competitive and innovate. They are conducting extensive research and development (R&D) activities, working on discovering new targets and optimizing existing therapies. Additionally, these companies are forming strategic partnerships with academic institutions, leveraging their expertise to fuel innovation. Apart from this, they are investing in cutting-edge manufacturing technologies to produce immunotherapy drugs efficiently and at scale. Furthermore, regulatory teams within these companies are collaborating with governmental bodies to ensure compliance with emerging rules and gain expedited approvals for novel treatment. Moreover, many companies are actively participating in international conferences and symposia, sharing knowledge, and learning from global peers.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • GSK plc
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.

Key Questions Answered in This Report

  • 1.How big is the global immunotherapy drugs market?
  • 2.What is the expected growth rate of the global immunotherapy drugs market during 2025-2033?
  • 3.What are the key factors driving the global immunotherapy drugs market?
  • 4.What has been the impact of COVID-19 on the global immunotherapy drugs market?
  • 5.What is the breakup of the global immunotherapy drugs market based on the drug type?
  • 6.What is the breakup of the global immunotherapy drugs market based on the therapy area?
  • 7.What is the breakup of the global immunotherapy drugs market based on the end user?
  • 8.What are the key regions in the global immunotherapy drugs market?
  • 9.Who are the key players/companies in the global immunotherapy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunotherapy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Interferons Alpha and Beta
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Interleukins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune and Inflammatory Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim International GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.